Monopar Therapeutics MNPR Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's accounts payable?
- Monopar Therapeutics (MNPR) reported accounts payable of $2.46M in Q1 2026.
- How has Monopar Therapeutics's accounts payable changed year-over-year?
- Monopar Therapeutics's accounts payable increased by 64.7% year-over-year, from $1.49M to $2.46M.
- What is the long-term trend for Monopar Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Monopar Therapeutics's accounts payable has grown at a 18.4% compound annual growth rate (CAGR), from $1.18M to $2.74M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.